Dare Bioscience (DARE) Short term Debt (2013 - 2025)

Dare Bioscience's (DARE) quarterly Short term Debt came in at $10542.0 in Q3 2025, down 94.39% on a QoQ basis from $187966.0 in Q2 2025.

Dare Bioscience (DARE) Short term Debt (2013 - 2025) Analysis & Trends

Dare Bioscience (DARE) has 8 years of Short term Debt data on file, last reported at $10542.0 in Q3 2025.

Quarterly Short term Debt changed N/A year-over-year to $10542.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $10542.0 (changed N/A YoY) and the FY2024 annual result came in at $4054.0, changed N/A from the prior year.
Short term Debt fell to $10542.0 in Q3 2025, from $187966.0 in the prior quarter.
In the past five years, Short term Debt ranged from a high of $1.0 million in Q1 2021 to a low of $4054.0 in Q4 2024.
A 3-year average of $382411.5 and a median of $139936.5 in 2025 frame the typical range for Short term Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.50 Bn	131.65 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.10 Bn	78.10 Bn	3.93 Bn
3	Argenx Se	65.59 Bn	60.41 Bn	1.37 Bn
4	Moderna	56.75 Bn	51.62 Bn	52.00 Mn
5	BeOne Medicines	42.11 Bn	37.01 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.64 Bn	28.33 Bn	992.69 Mn
7	BioNTech SE	27.80 Bn	9.41 Bn	668.28 Mn
8	Insmed	27.51 Bn	26.35 Bn	358.27 Mn
9	Royalty Pharma	27.29 Bn	26.45 Bn	-
10	Dare Bioscience	12.47 Mn	-142,892.36	-132,343.00

Download Data